Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ...

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...

Artelo Biosciences (ARTL) stock jumped 40% after announcing a fully-funded glaucoma trial for ART27.13 with Belfast Health and Social Care Trust.

Glaucoma is a leading cause of irreversible blindness worldwide and often goes undiagnosed until vision loss is advanced.

As the elderly population grows, the number of glaucoma patients continues to rise, with a notable increase observed among individuals in their 20s to 40s, necessitating heightened caution. Glaucoma ...

Nigeria’s leading eye care provider, Skipper Eye-Q Super Speciality Eye Hospital, Lagos, has called for increased glaucoma screening across the country, warning that many people remain unaware of the ...

Artelo Biosciences Inc (NASDAQ:ARTL) shares jumped 32.9% Wednesday following the company’s announcement of a study agreement with Belfast Health and Social Care Trust to evaluate its drug candidate ...

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Topical brimonidine is linked to a significantly increased risk for trabeculectomy failure in patients with glaucoma due to elevated intraocular pressure.

A comanagement program at UCSF in which patients saw glaucoma-trained optometrists and had access to glaucoma specialists showed promising outcomes, according to a study published in Ophthalmology ...

World Glaucoma Week 2026, a global campaign by the World Glaucoma Association mobilizing five continents from March 8 ...

In studies published so far, GLP-1 receptor agonists appear to be beneficial for the treatment of glaucoma, according to a review published in Cureus.“GLP-1 RAs exert both protective and adverse ...